Don't Expect the Antibiotic Plazomicin to Be Added to Your Hospital Formulary

You'll see the new aminoglycoside, plazomicin (Zemdri, ZEM-dree), promoted for carbapenem-resistant Enterobacteriaceae (CRE).

It works like other aminoglycosides and has the same side effects...nephrotoxicity, ototoxicity, etc.

The difference is that plazomicin isn't as affected by aminoglycoside-modifying enzymes...the most common cause of aminoglycoside resistance to E. coli and other Enterobacteriaceae.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote